Subscribe
4 September 2025NewsEuropeMarisa Woutersen

The flaw that landed Sanofi a win in the rare disease space

The company’s EPO victory over a rare disease biomarker patent highlights how precise claims and attention to objections can make or break biotech cases, reports Marisa Woutersen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Sanofi successfully challenges rare disease patent in Europe
1 July 2025   French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity.


Editor's picks

Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025

Editor's picks

Americas
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
3 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025

More on this story

Europe
Sanofi successfully challenges rare disease patent in Europe
1 July 2025   French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity.

More on this story

Europe
Sanofi successfully challenges rare disease patent in Europe
1 July 2025   French biopharma giant overturns German rival’s patent at the European Patent Office | Revocation based on insufficient disclosure of antibody production | Appeal focused on detection method claims and biomarker specificity.

More features

Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia
The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection